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We agree in principle with our colleagues’ endorsement in this
journal of the use of the tropomyosin receptor kinase (TRK)
inhibitor LOXO-101 (larotrectinib) in children.1 Our enthusiasm
for the accelerated deployment of LOXO-101 has been
tempered by our experience of multi-TRK inhibitor resistance
though. Resistance mutations to LOXO-101 do occur but can be
overcome by second- generation TRK inhibitors, such as LOXO-
195 (selitrectinib).2 We, however, report the emergence of































































Fig. 1 Evolution of multi-TRK resistance. a Clonal composition of tumour tissues over the course of illness. Coloured circles denote the clonal
composition of tissues sequenced at a given time point. The scale of a clone’s contribution to these samples is relative to a circle’s size; larger
circles indicate a greater contribution by that clone. Beneath this is a simplified overview of principal systemic therapies and the resultant
tumour responses. IVA ifosfamide, vincristine, actinomycin D, VIT vincristine, irinotecan, temozolomide, LOXO-101 (larotrectinib) first-
generation TRK inhibitor, LOXO-195 (selitrectinib) second-generation TRK inhibitor. Arrowheads tapering from left to right indicate partial/
complete tumour response and vice versa for progression. b Sequence of somatic alterations of NTRK3. Black line: ETV6-NTRK3 fusion. Grey line:
wild-type copy of NTRK3. Number of lines corresponds to copy number. Screen capture on the right shows the co-occurrence of both
resistance mutations on the same tumour sequencing reads. At the bottom are three coronal MRI images of the tumour (white arrow): one at
diagnosis (left) and two demonstrating the tumour’s best response to LOXO-101 (middle) and LOXO-195 (right). c Phylogenetic tree of tumour
lineages. Solid lines: major branches where mapped mutations revealed the relationship of the clones identified. Labelled overlying coloured
circles represent the clones shown in panel a. Dashed lines: private mutations that did not inform tree building.
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inhibitors in an NTRK-driven infantile fibrosarcoma (IFS). Our
case questions the introduction of TRK inhibitors into clinical
practice without the scrutiny of comparative clinical trials,
especially in the context of NTRK-driven childhood tumours that
are rarely lethal. Our cautionary words are particularly pertinent
in view of the recent approval to use LOXO-101 by the UK’s
National Institute for Health and Care Excellence.
Our patient, a 10-month-old girl, suffered from an anterior
mediastinal IFS extending into the neck that harboured a
canonical IFS-associated ETV6-NTRK3 gene fusion. We treated
her over a period of 12.5 months with cytotoxic chemotherapy,
first- and second-generation TRK inhibitors and two attempts at
complete surgical resection (Fig. 1a, b). The tumour repeatedly
regrew and ultimately led to the child’s death. To understand
the development of treatment resistance, we reconstructed the
evolution of the lethal clone from somatic mutations, obtained
by whole genome (fatal relapse) or exome sequences (seven
tissues obtained at diagnosis and after each recurrence).
At diagnosis, the tumour contained single copies of wild-type
NTRK3 and the ETV6-NTRK3 fusion (Fig. 1b). Analysis of the
first relapse revealed duplication of the ETV6-NTRK3 fusion.
At second relapse, after 2 months of treatment with a first-
generation TRK inhibitor (LOXO-101), we detected the NTRK3
resistance mutation, G623R,3 along with loss of the wild-type
NTRK3 gene. Then, following 2.5 months of treatment with a
second-generation TRK inhibitor (LOXO-195), multidrug resis-
tance emerged in the shape of two mutations, NTRK3 G623R and
F617L.3 Both were present in the same cells of the dominant
clone, as they were captured on the same reads (i.e. the same
DNA molecule) (Fig. 1b). Reconstructing the phylogeny of
tumour lineages from substitutions and small indels revealed
a complex clonal composition of the tumour, from which the
lethal, double- mutant clone emerged (Fig. 1c). These analyses
delineate the development of a seemingly “supercharged” ETV6-
NTRK3 resistance fusion, forged under the selective pressure of
TRK inhibitors.
The key evidence justifying the use of LOXO-101 in children
with NTRK-driven tumours is a phase 1/2 study, which showed
an impressive 93% objective response rate (ORR) amongst 15
children.4 Two of these with locally advanced disease even
achieved R0 resections following treatment with TRK inhibitors.
We note that one patient did develop the same NTRK3 G623R
resistance mutation as our patient although responded to a
second-generation inhibitor (selitrectinib). Recent work in a
mixed-age cohort across histologies suggests that a 45% ORR
can be achieved with LOXO-195 in patients with these NTRK
kinase domain mutations.3
On this basis, it would appear that TRK inhibition is an
attractive, non-cytotoxic strategy for tumour shrinkage prior to, or
even in lieu of, surgery in childhood tumours of low metastatic
potential, such as IFS. Our challenge has been that the same
marked clinical responses to both TRK inhibitors were seen in our
patient, yet were short lived and preceded the outgrowth of a
lethal tumour clone. Without access to long-term efficacy data or
head-to-head comparisons to best current practice, it is difficult
to know how representative our experience is and so highlights
the current challenge in identifying the most opportune moment
to utilise TRK inhibitors in the management of IFS. Clearly, in the
context of invariably lethal cancers, phase 1/2 studies may
provide sufficient evidence for utilising tumour-agnostic drugs.
However, in seldom lethal NTRK-driven childhood tumours, we
require comparative clinical trials beyond basket studies to learn
when and how to deploy these drugs. Until such evidence is
available, we would advocate a cautious use of TRK inhibitors in
children.
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